XNCR Xencor Inc stock chart & analysis
Conviction 0HealthcareScan · Fri, Nov 6, 2026Xencor Inc (XNCR) closed at $35.75 (+4.99%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 77, RS Rating 99, -1.9% from its 52-week high, +133.7% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why XNCR moved
From the StockSetups movers recaps that covered XNCR, newest first. A recap states what was known that day.
- Premarket+29.8%
Xencor (XNCR) is up 29.8% in premarket trading, at $32.65, on about 1.9 million shares versus a 20-day average near 1.4 million. Its market cap is about $1.9 billion.
Premarket Movers Oct 26, 2026: Why SPRC, CLRO, XNCR Are Up →
Financials as of Wed, Sep 30, 2026 · quarterly.
XNCR technical analysis
Trend
XNCR is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 36.7% above the 50-day ($26.17) and 104.9% above the 200-day ($17.46). ADX(14) at 32 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 77, in overbought territory. The MACD histogram is positive. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 0.5× its 20-day average. It trades about $51.1M a day on average. ATR(14) is $1.97, 5.5% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.10) shows distribution.
Key levels
The chart pattern's support is $22.27 and its resistance $29.98. The 52-week range is $10.38 to $36.48; price is 1.9% below the high and 244.8% above the low. The VWAP anchored at the 52-week high is $35.44, below price.
Performance
XNCR returned +20.0% (1 week), +46.0% (1 month), +65.8% (3 months), +178.2% (6 months), +149.0% (1 year), +133.7% (year to date).
About Xencor Inc
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Pharmaceutical Preparations · Listed 2013 · 260 employees
Recent news
- Xencor Inc: Ownership stake amendedSEC EDGAR · Thu, Nov 5, 2026
- Xencor Inc: Earnings resultsSEC EDGAR · Wed, Nov 4, 2026
Insider activity
SEC Form 4 transactions in XNCR
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Deshaies Raymond Joseph Director · Stock Option (Right to Buy) · 2026-06-16 | Grant | 20.6K | — | 2026-06-16 | 2026-07-08 |
Deshaies Raymond Joseph Director · Common Stock · 2026-06-16 | Grant | 10.3K | — | 2026-06-16 | 2026-07-08 |
Feigal Ellen Director · Common Stock · 2026-06-16 | Grant | 10.3K | — | 2026-06-16 | 2026-07-08 |
Feigal Ellen Director · Stock Option (Right to Buy) · 2026-06-16 | Grant | 20.6K | — | 2026-06-16 | 2026-07-08 |
GORMAN KEVIN CHARLES Director · Common Stock · 2026-06-16 | Grant | 10.3K | — | 2026-06-16 | 2026-07-08 |
GORMAN KEVIN CHARLES Director · Stock Option (Right to Buy) · 2026-06-16 | Grant | 20.6K | — | 2026-06-16 | 2026-07-08 |
GUSTAFSON KURT A Director · Common Stock · 2026-06-16 | Grant | 10.3K | — | 2026-06-16 | 2026-07-08 |
GUSTAFSON KURT A Director · Stock Option (Right to Buy) · 2026-06-16 | Grant | 20.6K | — | 2026-06-16 | 2026-07-08 |
Klencke Barbara Director · Common Stock · 2026-06-16 | Grant | 10.3K | — | 2026-06-16 | 2026-07-08 |
Klencke Barbara Director · Stock Option (Right to Buy) · 2026-06-16 | Grant | 20.6K | — | 2026-06-16 | 2026-07-08 |
SEC filings
EDGAR filings in XNCR · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.